Association of beta-3 integrin level with the presence and severity of coronary atherosclerosis in patients with chronic ischemic heart disease

Cover Page

Cite item

Full Text

Abstract

Relevance. Integrin beta‑3 is a critical molecule in several processes involved in the progression of atherosclerosis and coronary artery (CA) stenosis. Aim of the study is to identify the relationship between the serum level of integrin beta‑3 and the presence and severity of coronary atherosclerosis in patients with chronic coronary artery disease. Materials and methods. We examined 100 patients with chronic coronary artery disease who were referred for diagnostic coronary angiography (CAG) to verify the diagnosis of stable angina. All patients underwent instrumental and laboratory research methods, including determination of the levels of lipid fractions of blood serum using an enzymatic colorimetric method, as well as the level of beta‑3 integrin in blood serum using an enzyme-­linked immunosorbent assay. Statistical analysis was performed using the STATISTICA 12.0 package. Results and Discussion. According to the results of CAG, 32 patients did not have hemodynamically significant coronary lesions (coronary stenosis  < 50 %) (group 0), 32 patients had single-­vessel coronary lesions (stenosis > 50 %) (group 1) and 36 patients had multi-­vessel coronary lesions (group 2). Patients with multi-­vessel coronary artery disease were characterized by higher functional class of stable angina and degree of arterial hypertension, more often suffered a myocardial infarction and had a history of type 2 diabetes mellitus compared to patients without coronary lesions (p < 0.05). Patients in the group 0 had a lower level of integrin beta‑3 compared to patients of group 1 (p = 0.006) and group 2 (p = 0.002). Integrin beta‑3 level ≥92 pg/ml can be used to predict the development of stenotic coronary atherosclerosis (RR = 2.84; 95 % CI 1.54–5.22, p = 0.008). Conclusion. The results obtained indicate the important role of integrin beta‑3 in the pathogenesis of obstructive atherosclerotic lesions of the coronary arteries.

About the authors

Liudmila V. Kalatsei

Grodno State Medical University

Author for correspondence.
Email: lkolotsey@mail.ru
ORCID iD: 0000-0001-5211-709X
SPIN-code: 8435-3422
Grodno, Belarus

Yana R. Sagun

Grodno State Medical University

Email: lkolotsey@mail.ru
Grodno, Belarus

References

  1. Veselovskaya NG, Chumakova GA, Shenkova NN, Osipova ES, Gricenko OV. A model for predicting the risk of coronary atherosclerosis in patients with visceral obesity. Russian Journal of Cardiology. 2015;4;49–54. (in Russian) doi: 10.15829/1560–4071–2015–4–49–54
  2. Thomas MR, Lip GY. Novel Risk Markers and Risk Assessments for Cardiovascular Disease. Circ Res. 2017;120(1):133–149. doi: 10.1161/CIRCRESAHA.116.309955.
  3. Ginghina C, Bejan I, Ceck CD. Modern risk stratification in coronary heart disease. J Med Life. 2011;4(4):377–386.
  4. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. doi: 10.1016/S0140–6736(04)17018–9
  5. Sharma RK, Voelker DJ, Sharma R, Reddy HK, Dod H, Marsh JD. Evolving role of platelet function testing in coronary artery interventions. Vasc Health Risk Manag. 2012;8:65–75. doi: 10.2147/VHRM.S28090
  6. Sheikhvatan M, Boroumand MA, Behmanesh M, Ziaee S, Cheraghee S. Integrin Beta‑3 Gene Polymorphism and Risk for Myocardial Infarction in Premature Coronary Disease. Iran J Biotechnol. 2019;17(2): e1921. doi: 10.21859/ijb.1921
  7. Chen C, Li R, Ross RS, Manso AM. Integrins and integrin-­related proteins in cardiac fibrosis. J Mol Cell Cardiol. 2016;93:162–174. doi: 10.1016/j.yjmcc.2015.11.010
  8. Chernyak A.A., Snezhickij V.A. Prospects for the use of biomarkers (adiponectin, p-selectin, βΒ3 integrin) as biochemical predictors of restenosis in patients with coronary heart disease after coronary stenting. Journal of Grodno State Medical University. 2018;16(1):5–11. (in Russ.)
  9. Pang X, He X, Qiu Z, Zhang H, Xie R. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduct Target Ther. 2023;8(1):1. doi: 10.1038/s41392–022–01259–6
  10. Kokubo T, Uchida H, Choi ET. Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia. J Vasc Surg. 2007;45 Suppl A(6S): A33–A38. doi: 10.1016/j.jvs.2007.02.069
  11. Hoshiga M, Alpers CE, Smith LL, Giachelli CM, Schwartz SM. Alpha-v beta‑3 integrin expression in normal and atherosclerotic artery. Circ Res. 1995;77(6):1129–1135. doi: 10.1161/01.res.77.6.1129
  12. Finney AC, Stokes KY, Pattillo CB, Orr AW. Integrin signaling in atherosclerosis. Cell Mol Life Sci. 2017;74(12):2263–2282. doi: 10.1007/s00018–017–2490–4
  13. Yurdagul A, Sulzmaier FJ, Chen XL, Pattillo CB, Schlaepfer DD, Orr AW. Oxidized LDL induces FAK-dependent RSK signaling to drive NF-κB activation and VCAM‑1 expression. J Cell Sci. 2016;129(8):1580–1591. doi: 10.1242/jcs.182097
  14. Chen J, Green J, Yurdagul A, Albert P, McInnis MC, Orr AW. αvβ3 Integrins Mediate Flow-­Induced NF-κB Activation, Proinflammatory Gene Expression, and Early Atherogenic Inflammation. Am J Pathol. 2015;185(9):2575–2589. doi: 10.1016/j.ajpath.2015.05.013
  15. Hu HJ, Xiao XR, Li T, Liu DM, Geng X, Han M. Integrin beta 3‑overexpressing mesenchymal stromal cells display enhanced homing and can reduce atherosclerotic plaque. World J Stem Cells. 2023;15(9):931–946. doi: 10.4252/wjsc.v15.i9.931
  16. Estevez B, Shen B, Du X. Targeting integrin and integrin signaling in treating thrombosis. Arterioscler Thromb Vasc Biol. 2015;35(1):24–29. doi: 10.1161/ATVBAHA.114.303411
  17. Bogatyreva KB, Azova MM, Agadzhanyan AV, Ckhovrebova LV, Ait AA, Shugushev ZH. Association of the ITGB3 gene T1565C polymorphism with the development of atherosclerosis and in-stent restenosis in patients with stable coronary artery disease. Research Results in Biomedicine. 2018;4(4):3–9. (In Russian). doi: 10.18413/2313–8955–2018–4–4–0–1
  18. Papp E, Havasi V, Bene J, Komlosi K, Czopf L, Magyar E. Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation? Ann Pharmacother. 2005;39(6):1013–1018. doi: 10.1345/aph.1E227
  19. Izmozherova NV, Popov AA, Antropova IP, Kadnikov LI, Ispavskij VE, SHambatov M.A., Brazhenko G.G., Salov D.V. The role of the T1565C gene polymorphism, encoding beta‑3 integrin, in the development of thrombotic events and its impact on the effectiveness of antiplatelet therapy. Pathological physiology and experimental therapy. 2023;67(2):94–105. (In Russian).
  20. Zotova TY, Myandina GI, Frolov VA, Komarova AG, Zotov AK. The influence of ITGB3 gene polymorphism on the frequency of arterial hypertension in patients with acute coronary syndrome. Klin Med (Mosk). 2013;91(8):22–24. (In Russian)

Supplementary files

Supplementary Files
Action
1. Fig. 1. ROC curve of the development of stenotic coronary atherosclerosis depending on the integrin beta‑3 level

Download (97KB)
Indexing metadata

Copyright (c) 2024 Kalatsei L.V., Sagun Y.R.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies